Subcellular localization of Mdm2 expression and prognosis of breast cancer

Park, Hyung Seok; Park, Ji Min; Park, Seho; Cho, Junghoon; Kim, Kyung Sik; Park, Byeong Woo

doi:10.1007/s10147-013-0639-1

Cited by 29 publications

(28 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MDM2 protein levels have been identified as an independent prognostic biomarker in human BrC [(Park et al, 2014) and reference within it]. Abnormally high levels of MDM2 protein have been measured in at least 1/3 (38%) of human BrCs, which could not be explained by gene amplification alone (Yu et al, 2014).…”

Section: Disruption Of the Mdm Family Occurs In Brcmentioning

confidence: 99%

The role of MDM2 and MDM4 in breast cancer development and prevention

Haupt

Vijayakumaran

Miranda

et al. 2017

Journal of Molecular Cell Biology

View full text Add to dashboard Cite

The major cause of death from breast cancer is not the primary tumour, but relapsing, drug-resistant, metastatic disease. Identifying factors that contribute to aggressive cancer offers important leads for therapy. Inherent defence against carcinogens depends on the individual molecular make-up of each person. Important molecular determinants of these responses are under the control of the mouse double minute (MDM) family: comprised of the proteins MDM2 and MDM4. In normal, healthy adult cells, the MDM family functions to critically regulate measured, cellular responses to stress and subsequent recovery. Proper function of the MDM family is vital for normal breast development, but also for preserving genomic fidelity. The MDM family members are best characterized for their negative regulation of the major tumour suppressor p53 to modulate stress responses. Their impact on other cellular regulators is emerging. Inappropriately elevated protein levels of the MDM family are highly associated with an increased risk of cancer incidence. Exploration of the MDM family members as cancer therapeutic targets is relevant for designing tailored anti-cancer treatments, but successful approaches must strategically consider the impact on both the target cancer and adjacent healthy cells and tissues. This review focuses on recent findings pertaining to the role of the MDM family in normal and malignant breast cells.

show abstract

Section: Disruption Of the Mdm Family Occurs In Brcmentioning

confidence: 99%

The role of MDM2 and MDM4 in breast cancer development and prevention

Haupt

Vijayakumaran

Miranda

et al. 2017

Journal of Molecular Cell Biology

View full text Add to dashboard Cite

show abstract

“…A total of 291 patients with breast cancer at stage IV upon initially diagnosis, made between January 2001 and July 2014, were identified using the Severance breast cancer registry and the Severance metastatic breast cancer registry. The Severance breast cancer registry is a prospectively maintained database, described previously . In brief, the database includes information on the sex, age at the time of the diagnosis of stage IV breast cancer, T stage, nodal status, estrogen receptor (ER)/progesterone receptor (PR) status, human epidermal growth factor receptor 2/neu (HER2) amplification, tumor grade, and tumor subtype.…”

Section: Methodsmentioning

confidence: 99%

“…HER2 staining was considered positive in cases with an IHC score of 3+ or gene amplification as seen by fluorescence in‐situ hybridization (FISH), regardless of the HER2 IHC result. FISH analysis for HER2 was analyzed as previously described …”

Section: Methodsmentioning

confidence: 99%

“…The Severance breast cancer registry is a prospectively maintained database, described previously. 7 In brief, the database includes information on the sex, age at the time of the diagnosis of stage IV breast cancer, T stage, nodal status, estrogen receptor (ER)/progesterone receptor (PR) status, human epidermal growth factor receptor 2/neu (HER2) amplification, tumor grade, and tumor subtype. Tumor subtype is categorized into four subtypes based on immunohistochemical (IHC) staining of tumor samples: luminal A (ER + and PR+, HER2−), luminal B (ER+ and/or PR+, HER2+), HER2 over-expression (ER−, PR−, HER2+), and triple-negative breast cancer (TNBC; ER−, PR−, HER2−).…”

Section: Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Effect of primary tumor resection on overall survival in patients with stage IV breast cancer

Lim¹,

Kim²,

Park³

et al. 2019

Breast J

Self Cite

View full text Add to dashboard Cite

We aimed to evaluate the effect of primary tumor resection on overall survival in stage IV breast cancer patients. In total, 284 breast cancer patients presenting with breast cancer at stage IV at initial diagnosis, between 2001 and 2014, were enrolled in the study. Patients were divided into two groups based on surgical resection of the primary tumor. Overall survival (OS) between the two groups was analyzed. Patients in the surgery group (n = 92) had smaller tumors than those in the no‐surgery group (n = 192, T0‐1:17.7% vs 34.8%, P < 0.001). The surgery group more often had negative nodal status (5.7% vs 33.7%, P < 0.001). Multiple metastatic organ sites were more common in the no‐surgery group than in the surgery group (55.7% vs 15.2%, P < 0.001). The surgery group showed a better OS than the no‐surgery group (P = 0.01). Multivariate analysis showed that surgical resection of primary tumors tended to be associated with improved OS (HR = 0.67, P = 0.055). T stage, ER, HER2 and metastatic organ sites were independent prognostic factors for OS in multivariate analysis. Surgical resection of the primary tumor may be a treatment option for patients with stage IV disease and may not have a negative effect on overall survival.

show abstract

“…MDM2 promotes tumor formation by targeting tumor suppressor genes (e.g., p53 and p16), and its overexpression has been detected in a variety of different cancers [37]. Okamoto et al [38] reported that MDM2 positivity in pretreatment biopsy specimens was significantly higher in the failure group than in the CR group among cStageIII ESCC patients treated with definitive CRT.…”

Section: Negative Biomarkers In Tissue Examinationmentioning

confidence: 99%

Novel Candidate Biomarkers of Chemoradiosensitivity in Esophageal Squamous Cell Carcinoma: A Systematic Review

Sato

Motoyama²,

Saito³

et al. 2016

Eur Surg Res

View full text Add to dashboard Cite

There is no doubt that, along with surgery, chemoradiotherapy is an important treatment for esophageal squamous cell carcinoma (ESCC). Patients who respond well to chemoradiotherapy obtain great benefits toward overcoming their cancer, and so a more favorable prognosis. On the other hand, patients who do not respond well have wasted valuable time and experienced severe toxicity and seriously diminished quality of life, only to have their cancer recur with an unfavorable prognosis. For this reason, a reliable biomarker of chemoradiosensitivity in ESCC has long been sought. In this review, we will enumerate recently reported candidate biomarkers of chemoradiosensitivity in ESCC that have the potential for future clinical application.

show abstract

Subcellular localization of Mdm2 expression and prognosis of breast cancer

Abstract: Concurrent nuclear and cytoplasmic Mdm2 expression was an independent prognostic factor in patients with breast cancer. Subcellular localization of Mdm2 expression should be considered in the evaluation of Mdm2 in breast cancer.

Cited by 29 publications

References 33 publications

The role of MDM2 and MDM4 in breast cancer development and prevention

The role of MDM2 and MDM4 in breast cancer development and prevention

Effect of primary tumor resection on overall survival in patients with stage IV breast cancer

Novel Candidate Biomarkers of Chemoradiosensitivity in Esophageal Squamous Cell Carcinoma: A Systematic Review

Contact Info

Product

Resources

About